Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

RAHWAY, N.J. - Merck & Co., Inc., known as MSD outside of the United States and Canada, has presented pivotal Phase 3 trial results for a new subcutaneous formulation of pembrolizumab, which could ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at ...

Data suggest that SC pembrolizumab is non-inferior to IV pembrolizumab in patients with newly diagnosed, advanced NSCLC.

Merck (MRK) announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of ...